Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDIA3 | P30101 | 3/20 | 0.89 |
| ▸ | PDIA6 | Q15084 | 3/20 | 0.89 |
| ▸ | PDIA4 | P13667 | 2/20 | 0.89 |
| ▸ | TXNDC5 | Q8NBS9 | 1/20 | 0.89 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21100898 | 1.00 | PDIA3 (0.89) | PDIA3PDIA6PDIA4TXNDC5NPC1 | |
| SCHEMBL21064822 | 0.94 | PDIA3 (1.00) | PDIA3PDIA6PDIA4TXNDC5NPC1 | |
| SCHEMBL21100897 | 0.94 | PDIA3 (1.00) | PDIA3PDIA6PDIA4TXNDC5NPC1 | |
| SCHEMBL21100872 | 0.94 | PDIA3 (1.00) | PDIA3PDIA6PDIA4TXNDC5NPC1 | |
| SCHEMBL21100899 | 0.94 | PDIA3 (1.00) | PDIA3PDIA6PDIA4TXNDC5NPC1 | |
| SCHEMBL25997758 | 0.87 | PDIA3 (0.85) | PDIA3PDIA6PDIA4TXNDC5HPGD | |
| SCHEMBL21100772 | 0.83 | PDIA3 (0.68) | PDIA3PDIA6PDIA4TXNDC5 | |
| SCHEMBL21101061 | 0.80 | PDIA3 (0.74) | PDIA3PDIA6PDIA4TXNDC5NPC1 | |
| SCHEMBL21064814 | 0.79 | PDIA3 (1.00) | PDIA3PDIA6PDIA4TXNDC5 | |
| SCHEMBL21064818 | 0.79 | PDIA3 (1.00) | PDIA3PDIA6PDIA4TXNDC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731952-B2 | Indene derivatives and uses thereof | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731952-B2 | Indene derivatives and uses thereof | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-08-22 | — | — | US | disclosed |
| US-20200165182-A1 | INDENE DERIVATIVES AND USES THEREOF | Leukogene Therapeutics Incorporated | 2020-05-28 | — | — | US | disclosed |
| US-10329269-B2 | Indene derivatives and uses thereof | Leukogene Therapeutics Incorporated (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165182-A1 | INDENE DERIVATIVES AND USES THEREOF | CYP11B2, CYP1B1, CYP3A5 | PDIA3 736/4885PDIA6 1350/4885PDIA4 1280/4885 |
| US-11731952-B2 | Indene derivatives and uses thereof | CYP11B2, CYP1B1, CYP3A5 | PDIA3 736/4885PDIA6 1350/4885PDIA4 1280/4885 |
| US-10329269-B2 | Indene derivatives and uses thereof | CYP11B2, CYP1B1, CYP3A5 | PDIA3 736/4885PDIA6 1350/4885PDIA4 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.